⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL830188 | 0.61 | NOS3 (0.33) | — | |
| SCHEMBL17345694 | 0.61 | KDM4E (0.34) | — | |
| SCHEMBL8627877 | 0.58 | — | — | |
| SCHEMBL1013812 | 0.58 | — | — | |
| SCHEMBL830961 | 0.57 | NOS3 (0.36) | — | |
| SCHEMBL12151300 | 0.56 | — | — | |
| SCHEMBL487617 | 0.56 | HRH3 (0.55) | — | |
| SCHEMBL22382004 | 0.56 | NOS3 (0.34) | — | |
| SCHEMBL6465582 | 0.56 | NOS3 (0.44) | — | |
| Dimethylamine SCHEMBL9222538 | 0.56 | NOS3 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024108198-A2 | METHODS OF TREATING OBESITY WITH AN MC4R AGONIST | RHYTHM PHARMACEUTICALS, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| US-11058678-B2 | Substituted heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2021-07-13 | — | — | US | disclosed |
| US-20200316062-A1 | COMBINATIONS COMPRISING HISTONE DEACETYLASE INHIBITORS | KARUS THERAPEUTICS LIMITED (GB) | 2020-10-08 | — | — | US | disclosed |
| EP-3718573-A1 | CHROMOPHORIC POLYMER DOTS WITH NARROW-BAND EMISSION | University of Washington Through Its Center for Commercialization (US) | 2020-10-07 | — | — | EP | disclosed |
| EP-2797635-B1 | CHROMOPHORIC POLYMER DOTS WITH NARROW-BAND EMISSION | UNIV WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2020-05-20 | — | — | EP | disclosed |
| US-10544151-B2 | Compounds and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2020-01-28 | — | — | US | disclosed |
| US-20190224188-A1 | SUBSTITUTED HETEROCYCLES AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2019-07-25 | — | — | US | disclosed |
| EP-3036305-B1 | COMPOUNDS WITH TERMINAL HETEROARYLCYANOVINYLENE GROUPS AND THEIR USE IN ORGANIC SOLAR CELLS | BASF SE (DE) | 2019-04-17 | — | — | EP | disclosed |
| US-20190023710-A1 | NOVEL COMPOUNDS AND USES THEREOF | KALA BIO, Inc. | 2019-01-24 | — | — | US | disclosed |
| WO-2018133826-A1 | (HETERO)ARYLAMIDE COMPOUND FOR INHIBITING PROTEIN KINASE ACTIVITY | 深圳市塔吉瑞生物医药有限公司 | 2018-07-26 | — | — | WO | disclosed |
| US-20110151029-A1 | Paxillin Stimulating Compositions and Cosmetic Uses Thereof | AVON PRODUCTS, INC. (US) | 2011-06-23 | — | — | US | disclosed |
| US-7858642-B2 | Substituted hydroxyethylamine aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. (US) | 2010-12-28 | — | — | US | disclosed |
| WO-2010125102-A1 | 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-a]PYRAZINE DERIVATIVES AS P2X7 MODULATORS | GLAXO GROUP LIMITED (GB) | 2010-11-04 | — | — | WO | disclosed |
| US-20100261769-A1 | Topical Compositions Comprising Non-Proteogenic Amino Acids and Methods of Treating Skin | AVON PRODUCTS, INC. (US) | 2010-10-14 | — | — | US | disclosed |
| EP-1610789-B1 | BICYCLIC PIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS | MERCK SHARP & DOHME (US) | 2010-07-21 | — | — | EP | disclosed |
| US-20090270367-A1 | SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. | 2009-10-29 | — | — | US | disclosed |
| WO-2009058298-A1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK & CO., INC. (US) | 2009-05-07 | — | — | WO | disclosed |
| US-20080200405-A1 | Drug Resistance Reversal In Neoplastic Disease | COLBY PHARMACEUTICAL COMPANY | 2008-08-21 | — | — | US | disclosed |
| US-7414057-B2 | Piperazine urea derivatives as melanocortin-4 receptor agonists | MERCK & CO., INC. (US) | 2008-08-19 | — | — | US | disclosed |
| US-7414057-B2 | Piperazine urea derivatives as melanocortin-4 receptor agonists | MERCK & CO., INC. (US) | 2008-08-19 | — | — | US | disclosed |